News
Celon Pharma S.A. at the Jefferies Healthcare Conference 2021.
Representatives of the Management Board of Celon Pharma S.A. will take part in the 12th edition of the largest European conference on life science.
Doubled export sales, continuation of the strategy of investing in research and development
Net revenue from total sales in the first half of 2021 totalled PLN 105 million. Mostly due to export sales, which exceeded domestic sales. The majority of the Company’s products have maintained their market share in Poland, while the dynamic of the entire drug market in Poland has been decreasing.
Current report 42/2021 – Registration of D-series shares with the KDPW
The Management Board of Celon Pharma S.A. (the “Company”) hereby announces that it was informed of the publication of an announcement by Krajowy Depozyt Papierów Wartościowych S.A. on the registration in the securities depository of 6,000,000 of the Company’s ordinary D-series bearer shares under ISIN PLCLNPH00015 code on September 22, 2021
Current report 41/2021 – Supplement to Current Report No 35/2021 on the summary of subscription of ordinary D-series bearer shares of Celon Pharma S.A.
The Management Board of Celon Pharma S.A. (the “Company”) hereby publishes a supplement to current report No. 35/2021 dated July 29, 2021 regarding the costs related to the subscription of the Company’s ordinary D-series bearer shares (D-series Shares) referred to in items 12 and 13 of the aforementioned current report:
Current report 40/2021 – Admission and introduction of ordinary D-series bearer shares of the Company to stock exchange trading
The Management Board of Celon Pharma S.A. (the “Company”) hereby announces that on 15 September 2021 the Management Board of the Warsaw Stock Exchange (“GPW”) has adopted a resolution concerning the admission and introduction of the Company’s ordinary D-series bearer shares to stock exchange trading on the GPW Main Market List.
Current report 39/2021 – Conditional registration of the Company’s D-series shares with the KDPW
The Management Board of Celon Pharma S.A. (the “Company”) hereby informs about the statement of the Central Securities Depository of Poland (Krajowy Depozyt Papierów Wartościowych S.A. (“KDPW”), issued on 14 September 2021, on conditional registration in the depository of securities, under ISIN PLCLNPH00015 code; 6,000,000 ordinary D-series bearer shares of the Company with a nominal value of PLN 0.10 each.
3 posters to be published at 34th ECNP Congress
The 34th ECNP Congress will take place on October 2-5 in Lisbon. This is the most important European scientific meeting dedicated to brain research for disease. Each year, this event attracts over 5,000 psychiatrists, neurologists and psychologists from around the world. During the 34th ECNP Congress, posters will be presented. Posters by Sylwia Janowska –Read more »
Current report 38/2021 – Receipt of a notification regarding a change in the total number of votes in the Company
The Management Board of Celon Pharma S.A. informs that it has received the following notification from Mr. Maciej Wieczorek on a change in the total number of votes in the Company:
Current Report 37/2021 – Registration of share capital increase and amendments to the Company’s Articles of Association
Management Board of Celon Pharma S.A. (“Company”) informs that on September 9, 2021 the Regional Court for the Capital City of Warsaw in Warsaw, 14th Commercial Division of the National Court Register (the “Court”) registered the increase of the Company’s share capital as a result of the issuance of D-series shares within the authorized capital, conducted on the basis of the Resolution No. 4/2021 February 16, 2021 and the resolution of the Management Board of the Company of June 25, 2021. (current reports 9/2021 and 29/2021).
Current Report 36/2021 – Successful completion of Phase I clinical trial of the CPL’116 compound, the world’s first dual JAK/ROCK inhibitor
In connection with current report 6/2021 on completing a Phase IA clinical trial of an innovative JAK/ROCK kinase inhibitor (CPL’116) with potential therapeutic efficacy in autoimmune diseases, the Company wishes to announce that on 08/09/2021 it received information on the completion of the administration of the studied compound CPL’116 to healthy volunteers in Phase IB clinical trial. This means the completion of the Phase I clinical trial for the compound.
